RT Journal Article
SR Electronic
T1 Brain atrophy in prodromal synucleinopathy is shaped by structural connectivity and gene expression
JF medRxiv
FD Cold Spring Harbor Laboratory Press
SP 2021.12.27.21268442
DO 10.1101/2021.12.27.21268442
A1 Shady Rahayel
A1 Christina Tremblay
A1 Andrew Vo
A1 Ying-Qiu Zheng
A1 Stéphane Lehéricy
A1 Isabelle Arnulf
A1 Marie Vidailhet
A1 Jean-Christophe Corvol
A1 ICEBERG Study Group
A1 Jean-François Gagnon
A1 Ronald B. Postuma
A1 Jacques Montplaisir
A1 Simon Lewis
A1 Elie Matar
A1 Kaylena Ehgoetz Martens
A1 Per Borghammer
A1 Karoline Knudsen
A1 Allan Hansen
A1 Oury Monchi
A1 Bratislav Misic
A1 Alain Dagher
YR 2021
UL http://medrxiv.org/content/early/2021/12/30/2021.12.27.21268442.abstract
AB Isolated REM sleep behaviour disorder (iRBD) is a synucleinopathy characterized by abnormal behaviours and vocalizations during REM sleep. Most iRBD patients develop dementia with Lewy bodies, Parkinson’s disease, or multiple system atrophy over time. Patients with iRBD exhibit brain atrophy patterns that are reminiscent of those observed in overt synucleinopathies. However, the mechanisms linking brain atrophy to the underlying alpha-synuclein pathophysiology are poorly understood. Our objective was to investigate how the prion-like and regional vulnerability hypotheses of alpha-synuclein might explain brain atrophy in iRBD.Using a multicentric cohort of 182 polysomnography-confirmed iRBD patients who underwent T1-weighted MRI, we performed vertex-based cortical surface and deformation-based morphometry analyses to quantify brain atrophy in patients (67.8 years, 84% men) and 261 healthy controls (66.2 years, 75%) and investigated the morphological correlates of motor and cognitive functioning in iRBD. Next, we applied the agent-based Susceptible-Infected-Removed model (i.e., a computational model that simulates in silico the spread of pathologic alpha-synuclein based on structural connectivity and gene expression) and tested if it recreated atrophy in iRBD by statistically comparing simulated regional brain atrophy to the atrophy observed in patients. The impact of SNCA and GBA gene expression and brain connectivity was then evaluated by comparing the model fit to the one obtained in null models where either gene expression or connectivity was randomized.The results showed that iRBD patients present with cortical thinning and tissue deformation, which correlated with motor and cognitive functioning. Next, we found that the atrophy simulated based on brain connectivity and gene expression recreated cortical thinning (r=0.51, p=0.0007) and tissue deformation (r=0.52, p=0.0005) in patients, and that the connectome’s architecture along with SNCA and GBA gene expression contributed to shaping atrophy in iRBD. We further demonstrated that the full agent-based model performed better than network measures or gene expression alone in recreating the atrophy pattern in iRBD.In summary, atrophy in iRBD is extensive, correlates with motor and cognitive functioning, and can be recreated using the dynamics of agent-based modelling, structural connectivity, and gene expression. These findings support the concepts that both prion-like spread and regional susceptibility account for the atrophy observed in prodromal synucleinopathies. Therefore, the agent-based Susceptible-Infected-Removed model may be a useful tool for testing hypotheses underlying neurodegenerative diseases and new therapies aimed at slowing or stopping the spread of alpha-synuclein pathology.Competing Interest StatementShady Rahayel, Christina Tremblay, Andrew Vo, Ying-Qiu Zheng, Stephane Lehericy, Marie Vidailhet, Jean-Francois Gagnon, Jacques Montplaisir, Simon Lewis, Elie Matar, Kaylena Ehgoetz Martens, Per Borghammer, Karoline Knudsen, Allan Hansen, Oury Monchi, Bratislav Misic, and Alain Dagher report no competing interests. Isabelle Arnulf reports consultancies with Idorsia Pharma and paid speaker bureau for UCB Pharma, unrelated to the study. Jean-Christophe Corvol reports fees for advisory boards for Biogen, Denali, Idorsia, Prevail Therapeutic, Theranexus, UCB, and grants from Sanofi and the Michael J. Fox Foundation, outside the current work. Ronald B. Postuma reports grants and personal fees from Roche, personal fees from Takeda, Teva Neurosciences, Biogen, Boehringer Ingelheim, Theranexus, GE HealthCare, Jazz Pharmaceuticals, Abbvie, Jannsen, Otsuko, Phytopharmics, Inception Sciences, and Paladin outside the submitted work.Funding StatementThe ICEBERG Study performed in Paris was funded by the Investissements d'Avenir, IAIHU-06 (Paris Institute of Neurosciences - IHU), ANR-11-INBS-0006, Fondation d'Entreprise EDF, Biogen Inc., Fondation Therese and Rene Planiol, unrestricted support for research on Parkinson's disease from Energipole (M. Mallart) and Societe Francaise de Medecine Esthetique (M. Legrand). The work was also supported by a grant from Institut de France to Isabelle Arnulf (Alice Study) and received funding from the program Investissements d'Avenir (ANR-10-IAIHU-06). The work performed in Montreal was supported by the Canadian Institutes of Health Research, the Fonds de recherche du Quebec - Sante, and the W. Garfield Weston Foundation. Jean-Francois Gagnon reports grants from the Fonds de recherche du Quebec - Sante, the Canadian Institutes of Health Research, the W. Garfield Weston Foundation, the Michael J. Fox Foundation, and the National Institutes of Health. Ronald B. Postuma reports grants and personal fees from the Fonds de recherche du Quebec - Sante, the Canadian Institutes of Health Research, The Parkinson Society of Canada, the W. Garfield Weston Foundation, the Michael J. Fox Foundation, the Webster Foundation, and the National Institutes of Health. This work was also funded by awards from the Canadian Institutes of Health Research Foundation Scheme and the Healthy Brains for Healthy Lives initiative to Alain Dagher. The work performed in Sydney was supported by an NHMRC Dementia Team Grant (1095127). Simon Lewis is supported by an NHMRC Leadership Fellowship (1195830). Elie Matar reports funding from the National Health and Medical Research Council, grant 2008565. The work performed in Aarhus was supported by funding from the Lundbeck Foundation, the Danish Parkinson's Disease Association, and the Jascha Foundation.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethics committee of the McGill University Health Centre gave ethical approval for this work.I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesThe agent-based SIR model is available at https://github.com/yingqiuz/SIR_simulator. The regional values of the tissue deformation, cortical thickness, and cortical surface area maps are available at https://github.com/srahayel/SIR-RBD.